Association driven by fewer major amputations ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity ...

A cohort study of liver transplant candidates with HCC suggested that local-regional therapy with yttrium-90 transarterial ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention recently, both in the media and in doctors’ offices. Originally developed as a treatment for type 2 diabetes, ...

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

Patients with type 2 diabetes and inflammatory arthritis who received GLP-1 RAs had lower rates of hypoglycemia, serious infections, and acute kidney injury vs those receiving SGLT2 inhibitors.

Also from GiCS: adjuvant immunotherapy in liver cancer, novel combo for pancreas cancer ...

In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...

“GLP-1 and GIP inhibitors are amazing medications at doing what they were developed for — managing blood sugar in people with type 2 diabetes and weight loss in obesity,” study co-author Kelly Allison ...

This comparative effectiveness study found that initiation of sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in individuals with type ...

The FDA is requesting that manufacturers of three GLP-1 receptor agonists remove information on risk for suicidal ideation and behavior from their labels following an investigation, the agency stated ...

Researchers say a woman struggling with obesity who couldn't resist eating fatty foods experienced declines in her cravings after taking tirzepatide, the GLP-1 weight-loss drug used in Mounjaro and ...